Mycio Wealth Partners LLC held its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,841 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Mycio Wealth Partners LLC’s holdings in Bristol-Myers Squibb were worth $426,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of BMY. Tradewinds Capital Management LLC increased its position in shares of Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares in the last quarter. Blue Chip Partners Inc. increased its position in shares of Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 17 shares in the last quarter. Proficio Capital Partners LLC increased its position in shares of Bristol-Myers Squibb by 29.6% in the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 504 shares in the last quarter. American National Bank increased its position in shares of Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares in the last quarter. Finally, Heritage Trust Co bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter valued at $123,000. Institutional investors own 69.51% of the company’s stock.

WARNING: “Mycio Wealth Partners LLC Has $426,000 Position in Bristol-Myers Squibb Company (BMY)” was published by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.watchlistnews.com/mycio-wealth-partners-llc-has-426000-position-in-bristol-myers-squibb-company-bmy/1701588.html.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.23% of the stock is owned by corporate insiders.

BMY has been the subject of a number of research reports. UBS AG reiterated a “buy” rating and set a $72.00 target price (up previously from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Vetr upgraded Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 target price for the company in a report on Monday, October 9th. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. BMO Capital Markets reiterated a “sell” rating and set a $49.00 target price on shares of Bristol-Myers Squibb in a report on Monday, September 4th. Finally, Citigroup Inc. increased their target price on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $64.93.

Shares of Bristol-Myers Squibb Company (BMY) opened at $60.99 on Tuesday. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $66.10. The stock has a market cap of $99,609.57, a PE ratio of 20.56, a P/E/G ratio of 2.40 and a beta of 1.18. The company has a quick ratio of 1.46, a current ratio of 1.59 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.20 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The firm’s revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.77 earnings per share. equities analysts predict that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were issued a $0.39 dividend. The ex-dividend date of this dividend was Thursday, October 5th. This represents a $1.56 annualized dividend and a yield of 2.56%. Bristol-Myers Squibb’s dividend payout ratio is currently 61.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.